Enclomiphene Citrate for Gynecomastia: What the Evidence Actually Shows

What Is Enclomiphene and Why Is It Used Off-Label for Gynecomastia?

Enclomiphene citrate is the pharmacologically active trans-isomer of clomiphene citrate, a mixed estrogen receptor agonist/antagonist that has been prescribed since the 1960s. Unlike racemic clomiphene (Clomid), enclomiphene acts almost exclusively as an estrogen receptor antagonist because it lacks zuclomiphene, the cis-isomer responsible for residual estrogenic activity [1].

Gynecomastia develops when the estrogen-to-androgen ratio at breast tissue shifts toward estrogen dominance. This can happen during puberty, with aging-related testosterone decline, during testosterone replacement therapy (TRT) due to aromatization, or from medications such as spironolactone and ketoconazole [2]. SERMs counteract this by competitively binding estrogen receptors in mammary tissue, blocking the proliferative signal that drives glandular growth.

Enclomiphene attracted clinical attention because Repros Therapeutics (now Allergan) advanced it through Phase III trials (ZA-301 and ZA-302) for male secondary hypogonadism, demonstrating that 12.5 mg and 25 mg daily doses raised total testosterone into the eugonadal range (from a baseline mean of roughly 228 ng/dL to above 450 ng/dL at 12 weeks) while preserving spermatogenesis [3]. The FDA issued a Complete Response Letter in 2015 citing manufacturing concerns, not efficacy or safety failures, and the drug never reached market.

Because enclomiphene raises endogenous testosterone while blocking estrogen signaling, prescribers began compounding it off-label for men with gynecomastia, particularly those who experienced breast tenderness or tissue growth on TRT.

How Enclomiphene Works at the Receptor Level in Gynecomastia

Enclomiphene binds estrogen receptor alpha (ERα) in two tissues that matter for gynecomastia: the hypothalamus and the breast. At the hypothalamus, estrogen receptor blockade removes negative feedback on GnRH pulse frequency, which increases pituitary LH and FSH secretion and, downstream, testicular testosterone production [4]. At the breast, ERα antagonism directly opposes the estrogen-driven ductal epithelial proliferation that produces palpable glandular tissue.

This dual action is the theoretical basis for its off-label use. A man with gynecomastia driven by a high estrogen-to-testosterone ratio could, in principle, get simultaneous correction from both directions: less estrogenic stimulation at the breast and more androgen production from the testes.

The distinction from racemic clomiphene matters clinically. Zuclomiphene has an elimination half-life of roughly 30 days compared to enclomiphene's 10-hour half-life, meaning it accumulates with daily dosing [5]. Because zuclomiphene acts as a partial estrogen agonist in some tissues, chronic racemic clomiphene use can paradoxically maintain or worsen estrogenic effects in sensitive individuals. Enclomiphene avoids this pharmacokinetic trap entirely.

What Direct Evidence Exists for Enclomiphene in Gynecomastia?

No published randomized controlled trial, prospective cohort study, or systematic case series has evaluated enclomiphene citrate specifically for gynecomastia as a primary endpoint. The evidence is extrapolated from three sources: SERM class pharmacology, racemic clomiphene data, and mechanistic inference from the ZA-301/ZA-302 hypogonadism trials.

The strongest SERM evidence for gynecomastia comes from tamoxifen, not enclomiphene. A retrospective review of 220 patients treated with tamoxifen 20 mg daily for idiopathic gynecomastia showed complete resolution in 78% of cases after a median of 4.2 months, with partial response in another 12% [6]. The Endocrine Society's 2018 guideline on gynecomastia evaluation and management conditionally recommends SERMs for recent-onset, painful gynecomastia when watchful waiting is not preferred, noting that tamoxifen has more supporting data than raloxifene or other class members [2].

For racemic clomiphene specifically, a small double-blind crossover trial (N=12) published in the Journal of Clinical Endocrinology & Metabolism found that clomiphene 50 mg twice daily for 6 months produced a statistically significant reduction in breast size measured by ultrasound, though the clinical effect was modest [7]. The study was limited by its small sample size and the use of racemic drug.

Enclomiphene's Phase III hypogonadism data (ZA-301, N=253; ZA-302, N=242) did not measure gynecomastia as a pre-specified outcome, but adverse-event monitoring reported low rates of breast-related complaints in the treatment arms compared to topical testosterone gel controls [3]. This is consistent with the expected pharmacology but does not constitute direct efficacy evidence for established gynecomastia.

The honest summary: enclomiphene is pharmacologically plausible for gynecomastia, supported by class-effect reasoning and indirect data, but it lacks the direct clinical trial evidence that tamoxifen has accumulated over decades.

How Enclomiphene Compares to Other Medical Treatments for Gynecomastia

Three medications are used off-label for gynecomastia with varying levels of evidence. Their profiles differ in ways that affect prescribing decisions.

Tamoxifen remains the best-studied option. The 78% complete response rate in the largest retrospective series, combined with decades of breast cancer data establishing its safety profile, makes it the default medical treatment referenced in the Endocrine Society guideline [2][6]. Standard dosing is 10 to 20 mg daily for 3 to 6 months. Side effects include hot flashes, leg cramps, and (rarely) venous thromboembolism.

Raloxifene showed a 91% improvement rate in a small uncontrolled study (N=38) of pubertal gynecomastia at 60 mg daily for 3 to 9 months, though "improvement" was defined broadly and the study lacked a control arm [8]. Raloxifene may carry a lower risk of hot flashes than tamoxifen.

Aromatase inhibitors (anastrozole, letrozole) reduce estrogen production rather than blocking its receptor. A randomized, double-blind, placebo-controlled trial of anastrozole 1 mg daily in 80 boys with pubertal gynecomastia showed no statistically significant difference from placebo in breast volume reduction at 6 months [9]. The Endocrine Society guideline recommends against aromatase inhibitors for gynecomastia based on this negative trial.

Enclomiphene occupies a theoretical niche: it may be preferred in men who need both gynecomastia management and preservation or restoration of endogenous testosterone (for example, men coming off exogenous testosterone or those with secondary hypogonadism who want to avoid TRT). The clean antagonist profile without zuclomiphene accumulation is its main differentiator from racemic clomiphene.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society's hypogonadism guideline, has noted that "SERMs are underutilized in men with symptomatic gynecomastia, partly because clinicians default to surgical referral before trying a medical approach that may resolve symptoms within a few months" [10].

Dosing Protocols Reported in Clinical Practice

Because no FDA-approved labeling exists for enclomiphene in any indication, dosing for gynecomastia is derived from the hypogonadism trial protocols and clinical experience.

The ZA-301 and ZA-302 trials used 12.5 mg and 25 mg daily, both administered orally as a single morning dose [3]. Most compounding pharmacy protocols for off-label use follow this range. Some clinicians start at 12.5 mg daily and titrate to 25 mg if serum testosterone response is insufficient at 4 to 6 weeks.

A typical off-label protocol reported in clinical practice includes baseline labs (total testosterone, free testosterone, estradiol, LH, FSH, hepatic panel, CBC), initiation at 12.5 mg or 25 mg daily, repeat labs at 6 to 8 weeks, and clinical reassessment of breast tenderness and tissue volume at 8 to 12 weeks. Treatment duration is generally 3 to 6 months, with re-evaluation to determine whether the underlying cause of the estrogen-androgen imbalance has been addressed.

Prescribers should be aware of two practical considerations. First, enclomiphene is only available through compounding pharmacies, which means batch-to-batch variability is possible and patients should use 503B outsourcing facilities subject to FDA oversight when available [11]. Second, because enclomiphene raises LH and endogenous testosterone, it is not appropriate for men on concurrent exogenous testosterone, which suppresses LH through negative feedback. It is suited for men who are either off testosterone or who are using it as an alternative to exogenous testosterone.

Who Is a Candidate and Who Is Not

The clearest candidate for off-label enclomiphene in gynecomastia is a man with recent-onset (under 12 months), symptomatic gynecomastia driven by a correctable estrogen-androgen imbalance, who also has secondary hypogonadism or wishes to preserve fertility. This profile takes advantage of enclomiphene's dual mechanism: estrogen blockade at the breast plus endogenous testosterone restoration.

Enclomiphene is not a good fit in several scenarios. Long-standing gynecomastia (over 12 months) involves fibrotic tissue replacement that does not respond to hormonal manipulation. The Endocrine Society guideline notes that medical therapy is most effective within the first 12 months of symptom onset, after which surgical excision becomes the primary option [2]. Gynecomastia caused by medications (spironolactone, digoxin, anti-androgens) requires discontinuation of the offending agent as the first step, not addition of a SERM. Gynecomastia from hepatic cirrhosis or adrenal tumors requires treatment of the underlying condition.

Men with a personal history of venous thromboembolism should use SERMs cautiously. While enclomiphene's thromboembolic risk has not been independently quantified, tamoxifen carries a well-documented 2- to 3-fold increase in VTE risk [12], and class-effect concerns apply to all SERMs until proven otherwise.

Any new breast mass in a male patient warrants evaluation to exclude male breast cancer before initiating hormonal therapy. Breast cancer accounts for <1% of all breast cancers but is disproportionately diagnosed at later stages in men due to low clinical suspicion [13].

Safety Profile and Monitoring

Enclomiphene's safety data comes primarily from the Phase III hypogonadism trials. In ZA-301 and ZA-302, treatment-emergent adverse events at 12.5 mg and 25 mg daily included headache (5.2%), nausea (2.8%), and dizziness (1.6%) [3]. No cases of venous thromboembolism, visual disturbances, or hepatotoxicity were reported in either trial, though the total exposure (roughly 500 patient-years across both studies) is modest compared to tamoxifen's decades of post-marketing surveillance.

Visual side effects deserve specific mention. Racemic clomiphene is associated with visual disturbances (blurred vision, scotomata, photophobia) in approximately 1.5% of users, attributed to the zuclomiphene isomer's estrogenic effects on the retina [14]. Enclomiphene, lacking zuclomiphene, showed no visual adverse events in Phase III data, though post-marketing surveillance for compounded formulations does not exist.

Recommended monitoring during off-label use includes:

• Baseline: total testosterone, free testosterone, estradiol, LH, FSH, SHBG, hepatic panel, CBC, lipid panel
• 6 to 8 weeks: repeat hormonal panel to confirm testosterone response and estradiol suppression
• 12 weeks: clinical assessment of gynecomastia (tenderness, palpable tissue volume), repeat labs
• Ongoing: hepatic panel every 3 to 6 months if treatment extends beyond the initial course

Clinicians should also monitor hematocrit, as rising endogenous testosterone can stimulate erythropoiesis, though the effect is typically less pronounced than with exogenous testosterone administration [15].

The Regulatory and Access Field

Enclomiphene citrate has no FDA-approved indication for any condition. Repros Therapeutics submitted a New Drug Application for secondary hypogonadism that received a Complete Response Letter in December 2015 [3]. The intellectual property subsequently changed hands, and as of early 2026 no sponsor has resubmitted for approval.

Patients access enclomiphene through compounding pharmacies operating under Section 503A (patient-specific prescriptions) or Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act [11]. The FDA has not placed enclomiphene on its "difficult to compound" list, and it is available as an oral capsule or tablet from multiple compounders.

The lack of FDA approval means no insurance coverage. Out-of-pocket cost at compounding pharmacies typically ranges from $40 to $120 per month for a 25 mg daily supply, varying by pharmacy and geographic region. This compares favorably to branded tamoxifen alternatives but is less relevant given that generic tamoxifen costs under $15 per month at most retail pharmacies.

Prescribers writing for compounded enclomiphene should document the clinical rationale for off-label use, the patient's informed consent acknowledging the investigational nature of the treatment, and the monitoring plan. This documentation is standard practice for off-label prescribing but particularly important for a drug that never received FDA approval in any indication.

What the Endocrine Society and Other Guidelines Say

The Endocrine Society's 2018 Clinical Practice Guideline on gynecomastia evaluation and management does not mention enclomiphene by name [2]. Its conditional recommendation favoring SERMs for symptomatic recent-onset gynecomastia references tamoxifen and, to a lesser extent, raloxifene. The guideline grades the evidence for SERM use as low quality overall, reflecting the absence of large randomized trials even for tamoxifen.

The American Association of Clinical Endocrinologists (AACE) 2020 male hypogonadism guideline acknowledges SERMs as a treatment class for men with secondary hypogonadism who wish to preserve fertility, and notes that clomiphene citrate is the most commonly used agent in this class [16]. Enclomiphene is mentioned as an investigational agent that showed promise in Phase III but did not achieve approval. Neither AACE nor the Endocrine Society endorses enclomiphene specifically for gynecomastia.

Dr. Shalender Bhasin, professor of medicine at Harvard Medical School and principal investigator of the Testosterone Trials (TTrials), stated in a 2022 review that "the development of isomer-pure SERMs like enclomiphene represents a pharmacologic advance over racemic clomiphene, but clinical adoption has outpaced the evidence base, particularly for indications like gynecomastia where direct trial data do not exist" [17].

This gap between pharmacologic rationale and clinical evidence is the defining feature of enclomiphene's gynecomastia story. The drug makes mechanistic sense. It has a favorable side-effect profile compared to its parent compound. But the controlled trial data that would justify a guideline recommendation has never been generated.